The male hormone resetGroti Antonič, Kristina (Avtor) Zitzmann, Michael (Avtor) male hypogonadismtestosteroneGLP-1RAsobesitybonesosteoporosisIntroduction: Functional hypogonadism, a manifestation of testosterone deficiency in simultaneously present comorbidities, profoundly impairs quality of life in men with overweight and obesity - yet remains persistently under-recognized in clinical practice. Findings: Lifestyle modification constitutes first-line therapy, while pharmacological and surgical interventions increasingly complement it. Both promote substantial weight loss and may reverse obesity-related hypogonadism; bariatric surgery, in particular, elicits marked rises in circulating testosterone but entails risks of bone demineralization and uncertain long-term reproductive sequelae. Notwithstanding, testosterone deficiency itself represents a key driver of secondary osteoporosis, insulin resistance, anemia, fatigue, and depression as well as sexual symptoms. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have redefined obesity therapy through profound weight reduction and cardiometabolic benefit, yet concomitant losses of lean mass raise concern over sarcopenia and skeletal fragility. Conclusion: This focused review article aims to present a comprehensive update on the latest data concerning combining testosterone therapy with contemporary anti-obesity pharmacotherapy as a new standard of care for obese men with functional hypogonadism, uniting metabolic, vascular, sexual, cognitive, and skeletal benefits within a comprehensive strategy to fortify corporeal resilience and enhance quality of life.20252025-12-23 08:47:22Neznano24874UDK: 616.4ISSN pri članku: 1473-0790DOI: 10.1080/13685538.2025.2601423COBISS_ID: 262655235sl